Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: standard injections Clear all
Completed Phase 1 Interventional

Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma

NCT00698776
View directory record Official record
Conditions
Myeloma
Interventions
Lenalidomide, Monocyte derived DCs loaded with KRN7000
Drug · Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Early Phase 1 Interventional Results available

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

NCT03153410
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab, IMC-CS4
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

Anhedonia, Development, and Emotions: Phenotyping and Therapeutics

NCT05487885
View directory record Official record
Conditions
Depression, Anhedonia
Interventions
Continuous theta burst stimulation (cTBS), Positive Affect Training, Ketamine Injectable Solution
Device · Behavioral · Drug
Lead sponsor
Erika Forbes
Other
Eligibility
15 Years to 25 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 25, 2026, 10:13 PM EDT
Withdrawn Not applicable Interventional

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

NCT05106192
View directory record Official record
Conditions
Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma, Non Hodgkin Lymphoma, Lymphomatoid Papulosis, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Follicular
Interventions
Med-Jet Injector, Triamcinolone Acetonide, Bexarotene 1% Top Gel, Nitrogen Mustard, Conventional syringe
Device · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Phase 3 Interventional

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

NCT00295763
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Thyrogen (thyrotropin alfa for injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Aurora, Colorado • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 25, 2026, 10:13 PM EDT
Enrolling by invitation Phase 3 Interventional

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

NCT05645536
View directory record Official record
Conditions
Breast Cancer
Interventions
TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years to 51 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
17
States / cities
Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

NCT04496219
View directory record Official record
Conditions
Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Superficial Bladder Urothelial Carcinoma
Interventions
Acupuncture Therapy, BCG Solution, Best Practice, Quality-of-Life Assessment, Questionnaire Administration
Device · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 25, 2026, 10:13 PM EDT
Recruiting Phase 2 Interventional

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428
View directory record Official record
Conditions
Carcinoma, Non-small-Cell Lung
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Stanford, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

NCT04763265
View directory record Official record
Conditions
Frown Lines
Interventions
Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics"
Biological
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Santa Monica, California • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Open-Label Influenza Vaccine Evaluation

NCT02872311
View directory record Official record
Conditions
Immune Response
Interventions
High Dose Influenza vaccine, Adjuvanted Influenza vaccine, Standard Dose Influenza vaccine, Recombinant Influenza vaccine
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
65 Years to 74 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 25, 2026, 10:13 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

NCT04544267
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 25, 2026, 10:13 PM EDT
Recruiting Phase 3 Interventional

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244
View directory record Official record
Conditions
Acute Ischemic Stroke, Cerebral Stroke
Interventions
Drug: Normal Saline, Sovateltide
Drug
Lead sponsor
Pharmazz, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 25, 2026, 10:13 PM EDT
Withdrawn Phase 2 Interventional

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

NCT00514982
View directory record Official record
Conditions
Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions
Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 25, 2026, 10:13 PM EDT
Suspended Not applicable Interventional

Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy

NCT05206942
View directory record Official record
Conditions
Solid Tumor
Interventions
Doppler ultrasound, Long Ensemble Angular-coherence Doppler [LEAD] ultrasound, Contrast-enhanced ultrasound (CEUS)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

NCT03393013
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
KZR-616
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Los Angeles, California • Upland, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 25, 2026, 10:13 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

NCT06305286
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

NCT00970359
View directory record Official record
Conditions
Thyroid Cancer
Interventions
AZD6244
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Not applicable Interventional

Confirming Proper Replacement of Dislodged Gastrostomy Tubes in Pediatric Patients

NCT04331873
View directory record Official record
Conditions
Gastrostomy Tube Site Complication, Gastrostomy Complications
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
University of Tennessee
Other
Eligibility
0 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

Pudendal Enhancement of Enhanced Recovery After Surgery (ERAS) for Reconstructive Surgery (PEERS)

NCT04171050
View directory record Official record
Conditions
Pain Management
Interventions
Local anaesthetic, Pudendal Nerve Block plus anesthesia
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Not applicable Interventional

Adolescent Idiopathic Scoliosis (AIS) Gold Standard for Blood Loss

NCT03990376
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Radioisotope I-131-labeled albumin
Other
Lead sponsor
Emory University
Other
Eligibility
10 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 25, 2026, 10:13 PM EDT
Completed No phase listed Observational

Ferumoxytol Enhanced Hyperfine Low Field Strength MRI

NCT04721262
View directory record Official record
Conditions
Anemia, Hemolytic
Interventions
Hyperfine Portable MRI
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Not applicable Interventional

Impact of Osteopathic Manipulative Medicine on Sentinal Lymph Node Biopsy Dye and Tracer Uptake

NCT07269860
View directory record Official record
Conditions
Breast Cancer
Interventions
OMM prior to SLNB
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 25, 2026, 10:13 PM EDT
Completed Phase 1 Interventional

Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy -- Use in Acute Cholecystitis Sub-Study

NCT02070627
View directory record Official record
Conditions
Acute Cholecystitis, Acute Cholangitis
Interventions
Indocyanine Green (ICG), Near Infrared Fluorescence Cholangiography (NIRF-C)
Drug · Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 89 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 25, 2026, 10:13 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

NCT01165944
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pramlintide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 25, 2026, 10:13 PM EDT